Hikma Pharmaceuticals PLC
LSE:HIK
Hikma Pharmaceuticals PLC
Revenue
Hikma Pharmaceuticals PLC
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Revenue
$2.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Revenue
£30.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
AstraZeneca PLC
LSE:AZN
|
Revenue
$47.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Indivior PLC
LSE:INDV
|
Revenue
$1.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Revenue
£761.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
See Also
What is Hikma Pharmaceuticals PLC's Revenue?
Revenue
2.9B
USD
Based on the financial report for Dec 31, 2023, Hikma Pharmaceuticals PLC's Revenue amounts to 2.9B USD.
What is Hikma Pharmaceuticals PLC's Revenue growth rate?
Revenue CAGR 10Y
8%
Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Hikma Pharmaceuticals PLC have been 7% over the past three years , 7% over the past five years , and 8% over the past ten years .